{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T11:55:54Z","timestamp":1777722954646,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.clml.2018.05.014","type":"journal-article","created":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T05:30:33Z","timestamp":1527312633000},"page":"541-547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Impact of FLT3 Receptor (CD135) Detection by Flow Cytometry on Clinical Outcome of Adult Acute Myeloid Leukemia Patients"],"prefix":"10.1016","volume":"18","author":[{"given":"Eman Z.","family":"Kandeel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghada","family":"El Sayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahla","family":"Elsharkawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia Negm","family":"Eldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanan R.","family":"Nassar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia","family":"Ibrahiem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randa","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa","family":"Hanafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9744-1851","authenticated-orcid":false,"given":"Azza","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.05.014_bib1","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1158\/0008-5472.CAN-04-3081","article-title":"Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic\/severe combined immunodeficient mice","volume":"65","author":"Piloto","year":"2005","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2018.05.014_bib2","first-page":"3849","article-title":"Combination of omacetaxine mepesuccinate (homoharringtonine) and sorafenib as an effective regimen for acute myeloid leukemia (AML) carrying FLT3-ITD","volume":"130","author":"Leung","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.014_bib3","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1743-7563.2010.01322.x","article-title":"Clinical relevance of FLT3 receptor protein expression in Indian patients with acute leukemia","volume":"6","author":"Vora","year":"2010","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.014_bib4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11899-017-0381-2","article-title":"The future of targeting FLT3 activation in AML","volume":"12","author":"Leick","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2018.05.014_bib5","first-page":"1617","article-title":"Detailed analysis of FLT3 expression levels in acute myeloid leukemia","volume":"90","author":"Kuchenbauer","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.05.014_bib6","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1053\/j.seminhematol.2008.07.007","article-title":"Targeting FLT3 for the treatment of leukemia","volume":"45","author":"Small","year":"2008","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2018.05.014_bib7","first-page":"2140","article-title":"Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells","volume":"9","author":"Spiekermann","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.05.014_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/14728222.2014.960843","article-title":"Targeting FLT3 to treat leukemia","volume":"19","author":"Konig","year":"2015","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.clml.2018.05.014_bib9","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.014_bib10","first-page":"1","article-title":"The importance of FLT3 mutational analysis in acute myeloid leukemia","author":"Patnaik","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.05.014_bib11","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.05.014_bib12","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bjh.12299","article-title":"Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD","volume":"161","author":"Takahashi","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.05.014_bib13","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/cyto.b.21098","article-title":"Increased coexpression of c-KIT and FLT3 receptors on myeloblasts: independent predictor of poor outcome in pediatric acute myeloid leukemia","volume":"84","author":"Sharawat","year":"2013","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.clml.2018.05.014_bib14","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1111\/ijlh.12493","article-title":"FLT3 (CD135) and interleukin-2 receptor alpha-chain (CD25) expression in acute myeloid leukemia: improving the correspondence to FLT3\u2013internal tandem duplication mutation","volume":"38","author":"Abd El-Ghaffar","year":"2016","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.clml.2018.05.014_bib15","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1182\/blood.V122.21.2609.2609","article-title":"Disease characteristics and prognostic implications of cell surface FLT3 receptor (CD135) expression in pediatric acute myeloid leukemia\u2014a report from Children\u2019s Oncology Group","volume":"122","author":"Alonzo","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.014_bib16","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1158\/1078-0432.CCR-16-2353","article-title":"Disease characteristics and prognostic implications of cell-surface FLT3 receptor (CD135) expression in pediatric acute myeloid leukemia: a report from the Children\u2019s Oncology Group","volume":"23","author":"Tarlock","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.05.014_bib17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood.V112.11.147.147","article-title":"High level expression of wild type FLT3 is associated with poor outcome and selective sensitivity to FLT3 inhibitors in childhood acute myeloid leukemia: a Children\u2019s Oncology Group Study","volume":"112","author":"Brown","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.014_bib18","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2003-06-1845","article-title":"Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia","volume":"103","author":"Ozeki","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.014_bib19","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1182\/blood-2004-03-1036","article-title":"Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia","volume":"104","author":"Kern","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.014_bib20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/leu.2014.186","article-title":"Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse","volume":"29","author":"K\u00f6hnke","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.05.014_bib21","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.014_bib22","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","article-title":"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia","volume":"111","author":"Gale","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.014_bib23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.0902-4441.2003.00184.x","article-title":"Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies","volume":"72","author":"Graf","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2018.05.014_bib24","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40291-015-0170-3","article-title":"A\u00a0novel tandem duplication assay to detect minimal residual disease in FLT3\/ITD AML","volume":"19","author":"Lin","year":"2015","journal-title":"Mol Diagn Ther"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2018.05.014_bib25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/ijlh.12670","article-title":"Minimal residual disease in acute myelogenous leukemia","volume":"39","author":"Cruz","year":"2017","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.clml.2018.05.014_bib26","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/leu.2011.372","article-title":"Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia","volume":"26","author":"Hofmann","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.05.014_bib27","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bjh.12282","article-title":"Targeting of acute myeloid leukaemia by cytokine-induced killer cellsredirected with a novel CD123-specific chimeric antigen receptor","volume":"161","author":"Tettamanti","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.05.014_bib28","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1158\/0008-5472.CAN-14-1028","article-title":"FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia","volume":"74","author":"Ma","year":"2014","journal-title":"Cancer Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018301551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018301551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:37Z","timestamp":1761870637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018301551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S2152265018301551"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.05.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of FLT3 Receptor (CD135) Detection by Flow Cytometry on Clinical Outcome of Adult Acute Myeloid Leukemia Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}